Peer navigation support for Hispanic parents of children with cancer
Official title: Multisite Implementation of COMPRENDO (ChildhOod Malignancy Peer REsearch NavigatiOn) to Improve Participation of Hispanic Children in Cancer Clinical Trials
Run by University of California, San Diego · NCT06055296 · Data updated 2026-11-12
This study tests whether having trained peer supporters can help Hispanic parents of children with cancer get involved in clinical trials better than standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 4 sites (Birmingham, Alabama and 3 other locations) |
| Status | Recruiting |
| Started | January 11, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | June 3, 2026 |
| Trial ID | NCT06055296 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Hispanic parents or legal guardians of children aged 0-17 with newly diagnosed cancer or cancer-like diseases who are eligible for a therapeutic clinical trial.
✕Probably not a fit
Patients who have a second malignancy, are diagnosed at an outside institution, or do not understand written and spoken English or Spanish may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
COMPRENDO is a multi-site randomized clinical trial designed to evaluate the effectiveness of a peer-navigation intervention compared to usual care for increasing participation in childhood cancer clinical trials. The intervention involves trained peer navigators who will assist parents through four visits, focusing on informed consent and decision-making processes. The study will also assess implementation factors through mixed methods, including surveys and interviews with various stakeholders, to enhance the integration of peer navigation in clinical practice. Approximately 400 participants will be involved, with a focus on Hispanic families facing newly diagnosed pediatric cancers.
Why it matters
Potential benefit: If successful, this intervention could significantly improve clinical trial enrollment and parental understanding of informed consent in pediatric cancer care.
How similar studies have gone: Other studies have shown success with peer navigation interventions in improving clinical trial accrual and informed consent processes, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Non-Stakeholder/Stakeholder Parent Eligibility criteria: A parent/legal guardian who has a Hispanic child aged 0 to 17y with a new diagnosis of cancer, has a child who is eligible for a therapeutic cancer clinical trial, will participate in an informed consent discussion for the therapeutic clinical trial, understands written and spoken English or Spanish, and has signed the consent form for the proposed COMPRENDO study. Participants will not be eligible if their child has second malignancy/relapse, was diagnosed at an outside institution, has potential transfer of care, was previously on a clinical trial Stakeholder Clinician/Navigator/Administrator Clinicians, navigators and administrators who work at each site, are involved in treating pediatric patients and who are involved in the informed consent conference for clinical trials.
Where it's running
-
Children's of Alabama/University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting -
Rady Children's Hospital San Diego/University of California San Diego Moores Cancer Center
San Diego, California, United States Recruiting -
University of California San Francisco Benioff Children's Hospitals
San Francisco, California, United States Recruiting -
Dana Farber Cancer Institute/Boston Children's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: M.Paula Aristizabal, MD, MAS — University of California, San Diego
- Study coordinator: M.Paula Aristizabal, MD, MAS
- Email: paristizabal@rchsd.org
- Phone: 858-966-5811
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FaceSay: a computer program to help kids recognize facial expressions and improve social interactions
A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.
-
Access to Innovative Cancer Treatments for Children and Young People in Belgium
This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children
This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.
-
Laser thermal therapy for young people with low-grade glioma
This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.